Assessment of high-risk human papillomavirus infections and associated cervical dysplasia in HIV-positive pregnant women in Germany: a prospective cross-sectional two-centre study.


Journal

Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213

Informations de publication

Date de publication:
07 2023
Historique:
received: 09 08 2022
accepted: 13 12 2022
medline: 19 5 2023
pubmed: 29 12 2022
entrez: 28 12 2022
Statut: ppublish

Résumé

Invasive cervical cancer (ICC) is associated in nearly 100% with persistent high-risk Human Papillomavirus (HR-HPV) infection. ICC is still one of the leading causes for cancer mortality in women worldwide. The immunosuppressive influence of Human Immunodeficiency Virus (HIV) and the immunocompromised period of pregnancy due to tolerance induction against the hemiallogeneic fetus, are generally risk factors for acquisition and persistence of HR-HPV infections and their progression to precancerous lesions and HPV-associated carcinoma. Overall, 81 pregnant women living with HIV (WLWH) were included. A medical history questionnaire was used to record clinical and HIV data. Participants received cervicovaginal cytological smear, colposcopy and HPV testing. HPV test was performed using BSGP5+/6+ PCR with Luminex read-out. The HR-HPV genotypes 16, 18, 31, 33, 45, 52, 58 were additionally grouped together as high-high-risk HPV (HHR-HPV) for the purpose of risk-adapted analysis. HR-HPV prevalence was 45.7%. Multiple HPV infections were detected in 27.2% of participants, of whom all had at least one HR-HPV genotype included. HR-HPV16 and HR-HPV52 were the most prevalent genotypes and found when high squamous intraepithelial lesion (HSIL) was detected by cytology. HIV viral load of ≥ 50 copies/ml was associated with higher prevalence of HR-HPV infections. Whereas, CD4 T cells < 350/µl showed association with occurrence of multiple HPV infections. Time since HIV diagnosis seemed to impact HPV prevalence. Pregnant WLWH require particularly attentive and extended HPV-, colposcopical- and cytological screening, whereby clinical and HIV-related risk factors should be taken into account.

Identifiants

pubmed: 36576558
doi: 10.1007/s00404-022-06890-w
pii: 10.1007/s00404-022-06890-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

207-218

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1%3c12::AID-PATH431%3e3.0.CO;2-F
doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F pubmed: 10451482
World Health Organisation (WHO) (2021) WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV). WHO Publishing. https://www.who.int/publications/i/item/9789240040434 . Accessed 28 June 2022
Chesson HW, Dunne EF, Hariri S, Markowitz LE (2014) The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 41(11):660–664. https://doi.org/10.1097/OLQ.0000000000000193
doi: 10.1097/OLQ.0000000000000193 pubmed: 25299412 pmcid: 6745688
Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT et al (2012) Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 30(Suppl 5):F24-33. https://doi.org/10.1016/j.vaccine.2012.05.089
doi: 10.1016/j.vaccine.2012.05.089 pubmed: 23199964 pmcid: 3700362
Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S et al (2011) Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20(4):699–707. https://doi.org/10.1158/1055-9965.EPI-10-1108
doi: 10.1158/1055-9965.EPI-10-1108 pubmed: 21173170
Levi JE, Kleter B, Quint WG, Fink MC, Canto CL, Matsubara R et al (2002) High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol 40(9):3341–3345. https://doi.org/10.1128/jcm.40.9.3341-3345.2002
doi: 10.1128/jcm.40.9.3341-3345.2002 pubmed: 12202576 pmcid: 130803
Salcedo MM, Damin AP, Agnes G, Pessini SA, Beitune PE, Alexandre CO et al (2015) Prevalence of human papillomavirus infection in pregnant versus non-pregnant women in Brazil. Arch Gynecol Obstet 292(6):1273–1278. https://doi.org/10.1007/s00404-015-3752-8
doi: 10.1007/s00404-015-3752-8 pubmed: 25990479
Vyankandondera J, Wambua S, Irungu E, Mandaliya K, Temmerman M, Ryan C et al (2019) Type-specific human papillomavirus prevalence, incident cases, persistence, and associated pregnancy outcomes among HIV-infected women in Kenya. Sex Transm Dis 46(8):532–539. https://doi.org/10.1097/OLQ.0000000000001029
doi: 10.1097/OLQ.0000000000001029 pubmed: 31295222
Deutsche AIDS-Gesellschaft EV (DAIG) (2022) Frauen und HIV—gezielte Forschung ist notwendig. DAIG Publishing. https://daignet.de/site-content/die-daig/sektionen/aawsall-around-women-special#:~:text=Frauen%20und%20HIV%20%E2%80%93%20gezielte%20Forschung%20ist%20notwendig%20%E2%80%94%20Deutsche%20AIDS%20Gesellschaft%20e.V.&text=Ende%202020%20lebten%20in%20Deutschland,21%25 . Accessed 28 June 2022
Girardi F, Tirri Frey B, Küppers V, Menton M, Quaas J, Reich O (2012) Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011). Frauenarzt 53(11):1064–1066
Schmitt M, Dondog B, Waterboer T, Pawlita M (2008) Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 46(3):1050–1059. https://doi.org/10.1128/JCM.02227-07
doi: 10.1128/JCM.02227-07 pubmed: 18199790 pmcid: 2268381
Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G et al (2009) Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124(3):516–520. https://doi.org/10.1002/ijc.24010
doi: 10.1002/ijc.24010 pubmed: 18973271 pmcid: 2789446
Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K, Schmitt M et al (2016) VALGENT: A protocol for clinical validation of human papillomavirus assays. J Clin Virol 76(Suppl 1):S14–S21. https://doi.org/10.1016/j.jcv.2015.09.014
doi: 10.1016/j.jcv.2015.09.014 pubmed: 26522865
de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B et al (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11(11):1048–1056. https://doi.org/10.1016/S1470-2045(10)70230-8
doi: 10.1016/S1470-2045(10)70230-8 pubmed: 20952254
Griesser H, Marquardt K, Jordan B, Kühn W, Neis K, Neumann HH, Bollmann R, Pöschel B, Steiner M, Schenck U (2013) Münchner Nomenklatur III. Frauenarzt 54(11):1042–1048
Deutsche-Aids Gesellschaft EV (DAIG)—Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften EV (AWMF) (2020) Deutsch-Österreichische Leitlinie zur HIV-Therapie in der Schwangerschaft und bei HIV exponierten Neugeborenen. AWMF Publishing DAIG. https://www.awmf.org/uploads/tx_szleitlinien/055-002l_S2k_HIV-Therapie-Schwangerschaft-und-HIV-exponierten_Neugeborenen_2020-10_01.pdf . Accessed 28 June 2022
van den Dries L, Claassen MAA, Groothuismink ZMA, van Gorp E, Boonstra A (2017) Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls. Virology 509:133–139. https://doi.org/10.1016/j.virol.2017.06.014
doi: 10.1016/j.virol.2017.06.014 pubmed: 28644978
Wagner A, Skof AS, Sehouli J, Richter R, Henrich W, von Weizsacker K et al (2022) Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. Int J Gynecol Cancer 32(6):716–723. https://doi.org/10.1136/ijgc-2021-003327
doi: 10.1136/ijgc-2021-003327 pubmed: 35354606
Robert Koch Institut (RKI) (2020) HIV/AIDS in Deutschland—Eckdaten der Schätzung. RKI Publishing. https://www.rki.de/DE/Content/InfAZ/H/HIVAIDS/Eckdaten/EckdatenDeutschland.pdf?__blob=publicationFile . Accessed 28 June 2022
Palefsky JM (2003) Cervical human papillomavirus infection and cervical intraepithelial neoplasia in women positive for human immunodeficiency virus in the era of highly active antiretroviral therapy. Curr Opin Oncol 15(5):382–388. https://doi.org/10.1097/00001622-200309000-00007
doi: 10.1097/00001622-200309000-00007 pubmed: 12960521
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften EV (AWMF) (2020) S3-Leitlinie Prävention des Zervixkarzinoms. AWMF Publishing. https://www.awmf.org/uploads/tx_szleitlinien/015-027OLl_Praevention_Zervixkarzinom_2020-03-verlaengert.pdf . Accessed 28 June 2022
Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799. https://doi.org/10.1086/657321
doi: 10.1086/657321 pubmed: 21067372
Bollen LJ, Chuachoowong R, Kilmarx PH, Mock PA, Culnane M, Skunodom N et al (2006) Human papillomavirus (HPV) detection among human immunodeficiency virus-infected pregnant Thai women: implications for future HPV immunization. Sex Transm Dis 33(4):259–264. https://doi.org/10.1097/01.olq.0000187208.94655.34
doi: 10.1097/01.olq.0000187208.94655.34 pubmed: 16452834
Banura C, Franceschi S, van Doorn LJ, Arslan A, Kleter B, Wabwire-Mangen F et al (2008) Prevalence, incidence and clearance of human papillomavirus infection among young primiparous pregnant women in Kampala. Uganda Int J Cancer 123(9):2180–2187. https://doi.org/10.1002/ijc.23762
doi: 10.1002/ijc.23762 pubmed: 18711697
Meyrelles ARI, Siqueira JD, Hofer CB, Costa TP, Azevedo AP, Guimaraes BV et al (2012) HIV/HPV co-infection during pregnancy in southeastern Brazil: prevalence, HPV types, cytological abnormalities and risk factors. Gynecol Oncol 128(1):107–112. https://doi.org/10.1016/j.ygyno.2012.10.003
doi: 10.1016/j.ygyno.2012.10.003 pubmed: 23063764
Luo D, Peng M, Wei X, Pan D, Xue H, Xu Y et al (2021) Prevalence of human papillomavirus and genotype distribution in pregnant and non-pregnant women in China. Risk Manag Healthc Policy 14:3147–3157. https://doi.org/10.2147/RMHP.S288838
doi: 10.2147/RMHP.S288838 pubmed: 34349575 pmcid: 8326939
Condrat CE, Filip L, Gherghe M, Cretoiu D, Suciu N (2021) Maternal HPV infection: effects on pregnancy outcome. Viruses. https://doi.org/10.3390/v13122455
doi: 10.3390/v13122455 pubmed: 34960724 pmcid: 8707668
Michael CW, Esfahani FM (1997) Pregnancy-related changes: a retrospective review of 278 cervical smears. Diagn Cytopathol 17(2):99–107. https://doi.org/10.1002/(sici)1097-0339(199708)17:2%3c99::aid-dc4%3e3.0.co;2-j
doi: 10.1002/(sici)1097-0339(199708)17:2<99::aid-dc4>3.0.co;2-j pubmed: 9258616
Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M et al (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121(4):829–846. https://doi.org/10.1097/AOG.0b013e3182883a34
doi: 10.1097/AOG.0b013e3182883a34 pubmed: 23635684
Stanley MA, Sterling JC (2014) Host responses to infection with human papillomavirus. Curr Probl Dermatol 45:58–74. https://doi.org/10.1159/000355964
doi: 10.1159/000355964 pubmed: 24643178
Hillemanns P, Soergel P, Hertel H, Jentschke M (2016) Epidemiology and early detection of cervical cancer. Oncol Res Treat 39(9):501–506. https://doi.org/10.1159/000448385
doi: 10.1159/000448385 pubmed: 27614953
Fife KH, Katz BP, Roush J, Handy VD, Brown DR, Hansell R (1996) Cancer-associated human papillomavirus types are selectively increased in the cervix of women in the first trimester of pregnancy. Am J Obstet Gynecol 174(5):1487–1493. https://doi.org/10.1016/s0002-9378(96)70593-8
doi: 10.1016/s0002-9378(96)70593-8 pubmed: 9065116
Morrison EA, Gammon MD, Goldberg GL, Vermund SH, Burk RD (1996) Pregnancy and cervical infection with human papillomaviruses. Int J Gynaecol Obstet 54(2):125–130. https://doi.org/10.1016/0020-7292(96)02694-x
doi: 10.1016/0020-7292(96)02694-x pubmed: 9236309
Kim YH, Park JS, Norwitz ER, Park JW, Kim SM, Lee SM et al (2014) Genotypic prevalence of human papillomavirus infection during normal pregnancy: a cross-sectional study. J Obstet Gynaecol Res 40(1):200–207. https://doi.org/10.1111/jog.12155
doi: 10.1111/jog.12155 pubmed: 23815316
Chan PK, Chang AR, Tam WH, Cheung JL, Cheng AF (2002) Prevalence and genotype distribution of cervical human papillomavirus infection: comparison between pregnant women and non-pregnant controls. J Med Virol 67(4):583–588. https://doi.org/10.1002/jmv.10142
doi: 10.1002/jmv.10142 pubmed: 12116008
Schmeink CE, Melchers WJ, Hendriks JC, Quint WG, Massuger LF, Bekkers RL (2012) Human papillomavirus detection in pregnant women: a prospective matched cohort study. J Womens Health (Larchmt) 21(12):1295–1301. https://doi.org/10.1089/jwh.2012.3502
doi: 10.1089/jwh.2012.3502 pubmed: 23210493
Arany I, Tyring SK (1998) Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 9(5):268–271. https://doi.org/10.1258/0956462981922197
doi: 10.1258/0956462981922197 pubmed: 9639204
Dolei A, Curreli S, Marongiu P, Pierangeli A, Gomes E, Bucci M et al (1999) Human immunodeficiency virus infection in vitro activates naturally integrated human papillomavirus type 18 and induces synthesis of the L1 capsid protein. J Gen Virol 80(Pt 11):2937–2944. https://doi.org/10.1099/0022-1317-80-11-2937
doi: 10.1099/0022-1317-80-11-2937 pubmed: 10580055
Vernon SD, Hart CE, Reeves WC, Icenogle JP (1993) The HIV-1 tat protein enhances E2-dependent human papillomavirus 16 transcription. Virus Res 27(2):133–145. https://doi.org/10.1016/0168-1702(93)90077-z
doi: 10.1016/0168-1702(93)90077-z pubmed: 8384765
Meyrelles AR, Siqueira JD, Santos PP, Hofer CB, Luiz RR, Seuanez HN et al (2016) Bonafide, type-specific human papillomavirus persistence among HIV-positive pregnant women: predictive value for cytological abnormalities, a longitudinal cohort study. Mem Inst Oswaldo Cruz 111(2):120–127. https://doi.org/10.1590/0074-02760150393
doi: 10.1590/0074-02760150393 pubmed: 26872340 pmcid: 4750452
Travassos AG, Brites C, Netto EM, Fernandes Sde A, Rutherford GW, Queiroz CM (2012) Prevalence of sexually transmitted infections among HIV-infected women in Brazil. BMC Infect Dis 16(6):581–585. https://doi.org/10.1016/j.bjid.2012.08.016
doi: 10.1016/j.bjid.2012.08.016
Jalil EM, Duarte G, El Beitune P, Simoes RT, Dos Santos Melli PP, Quintana SM (2009) High prevalence of human papillomavirus infection among brazilian pregnant women with and without human immunodeficiency virus type 1. Int J Gynecol Obstet 2009:485423. https://doi.org/10.1155/2009/485423
doi: 10.1155/2009/485423
Carriero C, Fascilla FD, Cramarossa P, Lepera A, Bettocchi S, Vimercati A (2018) Colpocytological abnormalities in HIV infected and uninfected pregnant women: prevalence, persistence and progression. Int J Gynecol Obstet 38(4):526–531. https://doi.org/10.1080/01443615.2017.1373082
doi: 10.1080/01443615.2017.1373082
Ramautarsing RA, Phanuphak N, Chaithongwongwatthana S, Wit FW, Teeratakulpisarn N, Pankam T et al (2015) Cervical and anal HPV infection: cytological and histological abnormalities in HIV-infected women in Thailand. J Virus Erad 1(2):96–102. https://doi.org/10.1016/S2055-6640(20)30485-4
doi: 10.1016/S2055-6640(20)30485-4 pubmed: 27482398 pmcid: 4946687
Nasioutziki M, Chatzistamatiou K, Loufopoulos PD, Vavoulidis E, Tsampazis N, Pratilas GC et al (2020) Cervical, anal and oral HPV detection and HPV type concordance among women referred for colposcopy. Infect Agent Cancer 15:22. https://doi.org/10.1186/s13027-020-00287-7
doi: 10.1186/s13027-020-00287-7 pubmed: 32318115 pmcid: 7160926
Baay M, Lardon F, Vermorken JB, Verhoeven V, Avonts D, Van Royen P et al (2004) HPV in cervix and vagina. Sex Transm Infect 80(3):249–250. https://doi.org/10.1136/sti.2003.008383
doi: 10.1136/sti.2003.008383 pubmed: 15170017 pmcid: 1744825
Skorstengaard M, Thamsborg LH, Lynge E (2017) Burden of HPV-caused cancers in Denmark and the potential effect of HPV-vaccination. Vaccine 35(43):5939–5945. https://doi.org/10.1016/j.vaccine.2017.08.062
doi: 10.1016/j.vaccine.2017.08.062 pubmed: 28923423

Auteurs

Charlotte K Metz (CK)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany.

Anna S Skof (AS)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology, Laboratory for Gynaecological Tumor Immunology, HPV Laboratory, Augustenburger Platz 1, 13353, Berlin, Germany.

Jalid Sehouli (J)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology, Laboratory for Gynaecological Tumor Immunology, HPV Laboratory, Augustenburger Platz 1, 13353, Berlin, Germany.

Jan-Peter Siedentopf (JP)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany.

Pimrapat Gebert (P)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Biometry and Clinical Epidemiology, Charitéplatz 1, 10117, Berlin, Germany.

Fabian Weiss (F)

Ludwig-Maximilians-University (LMU), University Hospital, Department of Obstetrics and Gynecology, Marchioninistrasse 15, 81377, Munich, Germany.

Irene Alba Alejandre (I)

Ludwig-Maximilians-University (LMU), University Hospital, Department of Obstetrics and Gynecology, Marchioninistrasse 15, 81377, Munich, Germany.

Michaela Heinrich-Rohr (M)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute for Social Medicine, Epidemiology and Health Economic, Luisenstraße 57, 10117, Berlin, Germany.

Katharina Weizsaecker (K)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany.

Wolfgang Henrich (W)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany.

Andreas M Kaufmann (AM)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department for Gynecology, Laboratory for Gynaecological Tumor Immunology, HPV Laboratory, Augustenburger Platz 1, 13353, Berlin, Germany.

Irena Rohr (I)

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Obstetrics, Augustenburger Platz 1, 13353, Berlin, Germany. irena.rohr@charite.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH